Infections remain a major cause of mortality worldwide and the long-term consequences can be severe for those who survive. The cycle of infection is one of ‘bad bugs’, susceptible patients, acute disease and debilitating sequelae\(^1\). Pathogens are the aggressors, and the host immune system is responsible for the defence. However, the host immune system can also become destructive, and excessive innate immune activation is a major cause of infection-associated morbidity, exemplified by symptomatic urinary tract infections (UTIs), which are caused, in part, by excessive innate immune activation. Severe kidney infections (acute pyelonephritis) are a major cause of morbidity and mortality, and painful infections of the urinary bladder (acute cystitis) can become debilitating in susceptible patients. Disease severity is controlled at specific innate immune checkpoints, and a detailed understanding of their functions is crucial for strategies to counter microbial aggression with novel treatment and prevention measures. One approach is the use of bacterial molecules that reprogram the innate immune system, accelerating or inhibiting disease processes. A very different outcome is asymptomatic bacteriuria, defined by low host immune responsiveness to bacteria with attenuated virulence. This observation provides the rationale for immunomodulation as a new therapeutic tool to deliberately modify host susceptibility, control the host response and avoid severe disease. The power of innate immunity as an arbitrator of health and disease is also highly relevant for emerging pathogens, including the current COVID-19 pandemic.

Molecular determinants of disease severity in urinary tract infection

Ines Ambite\(^1\), Daniel Butler\(^1\), Murphy Lam Yim Wan\(^1\), Therese Rosenblad\(^1\), Thi Hien Tran\(^1\), Sing Ming Chao\(^2\) and Catharina Svanborg\(^1\)\(^\#\)

Abstract | The most common and lethal bacterial pathogens have co-evolved with the host. Pathogens are the aggressors, and the host immune system is responsible for the defence. However, immune responses can also become destructive, and excessive innate immune activation is a major cause of infection-associated morbidity, exemplified by symptomatic urinary tract infections (UTIs), which are caused, in part, by excessive innate immune activation. Severe kidney infections (acute pyelonephritis) are a major cause of morbidity and mortality, and painful infections of the urinary bladder (acute cystitis) can become debilitating in susceptible patients. Disease severity is controlled at specific innate immune checkpoints, and a detailed understanding of their functions is crucial for strategies to counter microbial aggression with novel treatment and prevention measures. One approach is the use of bacterial molecules that reprogram the innate immune system, accelerating or inhibiting disease processes. A very different outcome is asymptomatic bacteriuria, defined by low host immune responsiveness to bacteria with attenuated virulence. This observation provides the rationale for immunomodulation as a new therapeutic tool to deliberately modify host susceptibility, control the host response and avoid severe disease. The power of innate immunity as an arbitrator of health and disease is also highly relevant for emerging pathogens, including the current COVID-19 pandemic.
Advances in our understanding of the molecular determinants of UTI pathogenesis, focusing on specific host susceptibility factors and their consequences. The molecular basis of disease is discussed, as well as the key events that define disease severity, with different characteristics in the kidneys and the bladder. By contrast, we also describe asymptomatic bacteriuria (ABU) and the molecular characteristics that explain this protective state. These novel findings have major implications for the precision of future diagnostic and therapeutic practices, especially the use of immunotherapy to reduce the excessive immune activation and restore a functional defence.

**Asymptomatic bacteriuria**

The urinary tract is a preferred niche for bacterial growth, similar to the intestinal and respiratory tracts, which harbour a rich microflora. Certain bacterial strains, attenuated for virulence, can establish a 'symbiotic state' in individual hosts and persist long term. No evidence exists suggesting that ABU increases the risk of symptomatic infection — quite the contrary, in fact. Epidemiological studies have demonstrated that ABU reduces the risk of symptomatic infection and recommendations from the Infectious Diseases Society of America (IDSA) and European Association of Urology (EAU) are to leave ABU untreated.

ABU was discovered when urine cultures were first performed in the general population and defined as growth of >10^5 colony-forming units (cfu) per millilitre of urine in an asymptomatic individual. Asymptomatic bacterial carriage was found in ~1% of schoolgirls, 2–10% of pregnant women and >20% of individuals >70 years of age. Long-term follow-up studies demonstrated that asymptomatic carriage is protective, as the frequency of symptomatic UTI recurrences is reduced in patients with untreated ABU compared with patients treated with antibiotics. In a controlled prospective study of ABU, children treated with antibiotics were at an increased risk of symptomatic episodes compared with patients in whom ABU was left untreated. This observation is the rationale for deliberately establishing ABU in patients who are refractory to other therapies. Intravesical inoculation of ABU strains, such as *Escherichia coli* 83972, has been used successfully and protection has been demonstrated in various studies, including a placebo-controlled clinical trial. After deliberate inoculation with *E. coli* 83972 the time to a symptomatic episode was prolonged and the likelihood was decreased (11.3 versus 5.7 months; 15 versus 73 recurrences after 12 months). A friendly coexistence between bacteria and host, therefore, seems to be a highly desirable outcome.

**Virulence attenuation**

Early population-based studies revealed that most ABU strains lack the virulence factors that typically define APN strains, including P fimbriae, α-haemolysin, aerobactin and other virulence genes. The loss of the pathogenicity island (PAI) genes can result in a complete or partial loss of virulence function, further strengthening the argument that the strains have evolved away from the virulent phenotype. For example, attenuating mutations frequently affect fimbrial adhesins (P, type 1, S and F1C), α-haemolysin, aerobactin and other virulence genes. The loss of the pathogenicity island marker *malX*, as well as *iha* and *ompT*, is observed in ABU isolates. ABU strains produce substantially fewer siderophores such as aerobactin and enterobactin and less frequently express α-haemolysin, *iha* and *fyuA* (a high-PAI marker gene) than virulent strains.

The ABU strain *E. coli* 83972 has been used as a molecular model to study this gradual loss of virulence in human carriers. *E. coli* 83972 is characterized by a
develop severe acute disease, recurrent infections and chronic disease states. Pathogens can actively modify the host environment in which they persist by deletions (such as fimEAIC), multiple point mutations (such as papG and focD) and a premature stop codon (such as hlyA). Importantly, virulence attenuation has been found to occur in human hosts carrying E. coli 83972 (REFS 50,53,70). During ABU, rapid and distinct bacterial genome alterations occur in a host-specific manner, involving functionally important genes such as regulators of gene expression, metabolism and virulence. Interestingly, the host-specific mutation pattern was reproduced in patients who received the same strain on several occasions, suggesting a strong, host-specific adaptation pattern of ABU strains.

Inhibition of host gene expression by targeting RNA Pol II phosphorylation. ABU strains were further shown to actively suppress the transcription machinery. In the case of NlpD from ABU strains, the bacterial protein inhibits transcription and suppresses excessive host innate immune responses. NlpD treatment was shown to reduce inflammation and enhance bacterial clearance from infected bladders in vivo when recombinant NlpD was injected intraperitoneally before intravesical E. coli infection. The findings suggest major therapeutic potential for NlpD as a modifier of inflammation and illustrate the potential of molecules of bacterial origin as immunomodulatory agents.

Attenuated TLR4 activation and mucosal pathogen recognition. Targeting of host receptors by pathogens alerts the host to the presence of the bacteria. Their virulence factors act as ‘danger signals’ and the host responds by activating the innate immune response, potentially leading to disease. By contrast, in ABU, such responses are avoided and the relative inertia of the host mucosa has been associated with reduced innate immune recognition of the infecting bacteria. Host recognition of Gram-negative bacteria has been extensively studied. TLR4 controls the innate host response to Gram-negative bacterial infection inhibited after 24 h compared with the pre-inoculation sample in each patient, suggesting that bacteria actively modify the host response to promote their own survival.

Further investigation identified a mechanism used by ABU strains to actively suppress RNA polymerase II (Pol II)-dependent gene expression in the host by regulating crucial steps in the Pol II transcription cycle. The multi-protein Pol II complex catalyses the transcription of mRNA precursors and most snRNAs and microRNAs through a series of steps, called the RNA Pol II cycle. Phosphorylation of the C-terminal domain of the Pol II subunit RPB1 is required to initiate productive RNA elongation. E. coli 83972 suppressed several transcriptional activators (including FOSB, CTNNB1 and TFAP2A), activated transcriptional repressors (including DACH1, BANP and DDX20) and suppressed genes involved in transcription initiation and recognition of the TATA box-binding protein (TBP). Specifically, the ABU strain regulated promoter release and productive elongation by inhibiting the RNA Pol II phosphorylation complex and small nuclear RNAs (RNU6ATAC, RN75K, RN65ATAC, RNA28S5). The frequency of Pol II inhibition was higher among ABU strains and faecal strains than in APN strains, supporting an association with ABU and commensalism.
generally, but with considerable complexity, depending on the pathogen and the site of infection (Fig. 3).

Early studies in a mouse UTI model showed that Lps, later redefined as Tlr4 (REF. 10), is a major determinant of the host response to UTI. However, the mechanism of TLR4 activation was shown to differ between epithelial cells in the mucosal lining of the urinary tract and monocytes, which had been used as a model. Urothelial cells express TLR4, but not the co-receptors CD14 and MD2 (also referred to as LY96) and, as a result, LPS recognition is weak, unless soluble CD14 is present at the site of infection. This lack of reactivity explains why ABU strains persist without creating a state of chronic inflammation in the urinary tract mucosa (Fig. 3; TABLE 1). Importantly, bacteria that express TLR4 agonists, such as P fimbriae, can override this unresponsiveness by engaging different TLR4 coreceptors, such as glycosphingolipids. This mechanism provides mucosal membranes with a much needed, pathogen-specific solution for when to respond to bacteria in the lumen. If epithelial cells recognized LPS, the entire Gram-negative microflora would trigger TLR4 signalling and chronic inflammation in the intestine and at other mucosal sites.

*Attenuating TLR4 promoter polymorphisms in patients with ABU.* A protected, ABU-like phenotype was first observed in C3H/HeJ mice, which carry a point mutation in the Toll/interleukin-1 receptor (TIR) domain of TLR4 (REFS 9, 58, 59). Tlr4−/− mice are protected from symptomatic UTI. Mice carrying single Tlr4 adaptor gene deletions (Trif−/−, MyD88−/−) infected with

**Fig. 2 | Symptomatic infections and asymptomatic bacteriuria.**

| a | Acute pyelonephritis |
|---|---|
| **Symptoms** | Fever (>38°C), flank pain, general malaise, nausea or vomiting. |
| **Laboratory parameters** | Bacteriuria, fever, elevated circulating acute phase reactants (CRP) and pro-inflammatory cytokines, pyuria. |
| **Prevalence** | Cumulative frequency ~3% in children <11 years of age. Overall, ~30% recur and 60% of those keep recurring. Urosepsis occurs in about 30% of adults. |
| **Current treatment protocol** | Prolonged antibiotic treatment (1–2 weeks), using, for example, cephalosporins, fluoroquinolones or trimethoprim + sulfamethoxazole (TMP/SMX), depending on the resistance pattern of the infecting pathogen. |

| b | Acute cystitis |
|---|---|
| **Symptoms** | Suprapubic pain, dysuria, frequency, urgency. |
| **Laboratory parameters** | Bacteriuria, haematuria, pyuria and elevated urine cytokines. |
| **Prevalence** | Overall, ~10% of women have yearly episodes, >40% of women have one episode during their lifetime. Recurrences are common and often occur in clusters. |
| **Current treatment protocol** | Acute antibiotic treatment, 3–7 days of narrow-spectrum antibiotics as a first-line therapy, few effective new treatment options. |

| c | Asymptomatic bacteriuria |
|---|---|
| **No symptoms** | Asymptomatic, protected. |
| **Laboratory parameters** | Bacteriuria (>10⁵ cfu/ml of urine) without symptoms. A moderate local inflammatory response might occur. |
| **Prevalence** | Overall, ~1% in girls, 1–5% of premenopausal women, 2–10% in pregnant women, ~20% in healthy individuals >70 years of age. |
| **Current treatment protocol** | Recommended to leave untreated in the absence of risk factors. |
uroepathogenic *E. coli* develop an ABU-like state, owing to reduced inflammation and bacterial clearance. Consistent with these studies, *Cd14−/−* mice show increased bacterial numbers in urine and bladder tissues compared with wild-type mice, suggesting that like *Tlr4−/−* mice, *Cd14−/−* mice could develop ABU.

Clinical studies have provided evidence of TLR4 attenuation in patients with ABU. TLR4 expression was reduced compared with age-matched healthy participants, and this phenotype was attributed to attenuating TLR4 promoter polymorphisms not observed in symptomatic UTI. The identified promoter polymorphisms were shown to reduce TLR4 expression in reporter assays and were further associated with reduced IL-8, IL-6 and neutrophil responses in patients inoculated with *E. coli* 83972. However, genetic variants affecting TRAM, TRIF or MYD88 expression were not detected in these patients, indicating that the receptor rather than the adaptor proteins influences ABU establishment.

**From ABU to APN**

An unexpected observation has suggested that an ABU strain might become virulent if equipped with a single ‘super-virulence factor’, specifically, the *papG* adhesin gene. These findings contradict the dogma of virulence necessarily being multifactorial and suggest that a single super-virulence factor might suffice to orchestrate a molecular transition from ABU to APN in the host.

**Divergent effects of fimbriae**

The observation of the potential of a single super-virulence factor was made in patients with recurrent UTIs who were inoculated with the ABU strain *E. coli*.

---

**Molecular determinants of asymptomatic bacteriuria.** Asymptomatic bacteriuria (ABU) is explained by both bacterial factors and host determinants that facilitate symbiosis. **A** | Bacterial factors: ABU strains coexist with their hosts without triggering symptoms. Several mechanisms contribute to this effect. **Aa** | ABU strains do not provoke a potent innate immune response in the host owing to a lack of functional virulence genes. **Ab** | ABU strains modify the host environment by actively inhibiting host gene expression. They secrete inhibitors of host RNA polymerase II (Pol II) such as NlpD, which targets the Pol II phosphorylation complex and inhibits gene expression, including pro-inflammatory genes. **B** | Host determinants: Toll-like receptor 4 (TLR4) signalling controls many aspects of the innate response to urinary tract infection. TLR4 signalling is attenuated in patients with ABU. At least two mechanisms contribute to this effect. **Ba** | Attenuating TLR4 promoter polymorphisms are prevalent in patients with ABU. These polymorphisms reduce TLR4 expression and the inflammatory response to bacteriuria. **Bb** | Optimal TLR4 activation by lipopolysaccharide (LPS) requires co-receptors, such as CD14 and lymphocyte antigen 96 (MD2). As the bladder epithelium does not express surface CD14, the cells remain refractory to bacterial LPS alone and ABU strains do not efficiently activate TLR4 signalling. Virulence factors such as *F* fimbiae enable pathogens to overcome the lack of CD14 and trigger a TLR4-mediated inflammatory cascade. MyD88, myeloid differentiation primary response protein 88; PMN, polymorphonuclear neutrophil; TRAM, TRIF-related adaptor molecule; TRIF, Toll/interleukin 1 receptor (TIR) domain containing adapter-inducing interferon-β.
The reconstituted strains were used for human inoculation and five patients inoculated with *E. coli* 83972 or *E. coli* 83972*fim* on different occasions, developed ABU. Unexpectedly, two of the patients who received *E. coli* 83972*pap* became symptomatic. The patients were treated with antibiotics, their symptoms resolved, and the study was discontinued. The molecular basis of the symptomatic response was investigated using genome-wide transcriptomic analysis technology (Fig. 5). *E. coli* 83972*pap* was found to reprogramme host gene expression, including genes in the interferon pathway and the pattern receptor recognition (PRR) pathway, which were activated. At the time of symptoms, regulated genes also included *IRF7*, *OAS3*, *OAS1* and *OAS2*, complement components, *IFIH1* (which encodes *MDA5*), *DDX58* (which encodes *RIG-I*), *IL1B*, *NLR4* (which encodes *IPAF*), *TNF*, *RIPK2* (which encodes *RIP2*), *IL6* and *NOD2*, several of which have been highly implicated in UTI pathogenesis. A strong *IRF7* response was detected in samples taken close to the symptomatic episodes,[46,79] confirming observations in the mouse UTI model, in which *IRF7* has been identified as a major regulator of the disease response during APN. Other identified transcriptional nodes included *IRF3* and *STAT1*, which regulate the protective, type I interferon-dependent response.[15] The PapG adhesin protein was further shown to enter host cells and to regulate *IRF7* expression by direct promoter binding, affecting the *IRF7* transcription complex assembly, together with *IRF3*, *MYC* and *IFNβ*.[17] These findings provide a mechanism for how classical transcriptional regulators might contribute to the pathophysiology of APN and be the link to *IRF7*-driven disease.[15]

By contrast, the *fim* reconstituted strain *E. coli* 83972*fim* was shown to attenuate host gene expression, inhibiting genes involved in RNA processing, post-transcriptional regulation and ribosome biogenesis (Fig. 5). No evidence of inflammation was observed and pro-inflammatory gene sets were not significantly regulated (cut-off of *P* < 0.05 compared with the pre-inoculation sample in each patient). Furthermore, effects on gene expression did not include *IRF7* or *IRF*-dependent genes.

The results suggest that type 1 fimbriae enhance the inhibitory effects of *E. coli* 83972 on host gene expression by affecting the post-transcriptional environment in infected hosts (Fig. 5). The analysis also revealed moderate activation of potassium channels, ion anti-porters, voltage-gated cation channels and substrate-specific ion channels. Activated genes also affected neuromodulatory signalling, sensory perception of pain, neurotransmitter receptors and nervous system development. These gene profiles are interesting as type 1 fimbriae have been associated with acute cystitis,[44-48], in which ion channel activation can lead to neuromodulatory activation, causing pain, urgency and frequency.

These results suggest that *P* fimbriae highjack the transcriptional machinery of the host, creating a fimbriae-specific gene expression profile. *P* fimbriae are expressed by 95–100% of APN isolates in patients without underlying disorders,[88] suggesting that expression of these adhesive ligands is essential for the
pathogenesis of APN. Thus, loss of P fimbriae would be a first step towards virulence attenuation and adaptation to long-term persistence in the urinary tract. This possibility is supported by a high frequency of inactivating papG mutations in ABU isolates. These findings suggest that virulence gene attenuation could be a new therapeutic alternative to antibiotics for treating UTI, focusing on super-virulence gene attenuation rather than indiscriminate removal of the bacteria. The results further suggest that ABU strains without functional P fimbriae would be preferred for use for human inoculation.

These findings further illustrate the remarkably divergent effects of P fimbriae and type 1 fimbriae, in infected hosts. Specifically, P fimbriae act as agonists of IRF7 and of downstream genes associated with APN. The response to E. coli 83972Δfim suggests novel cellular targets that need further study.

### Acute pyelonephritis

APN is a worst-case scenario and the opposite of ABU. UPEC strains attack the renal pelvic mucosa and can invade the renal parenchyma and reach the blood stream, causing urosepsis. Systemic involvement gives rise to fever (>38 °C), elevated C-reactive protein (CRP) in blood and general malaise, owing to the spread of innate immune mediators, such as IL-6, from the site of infection. In addition to the acute morbidity and mortality associated with APN, chronic tissue damage is common and renal tissue damage can cause focal scar formation, growth retardation and loss of function.

### Triggering the host response in APN

APN is caused by excessive innate immune activation in infected kidneys, which is controlled by TLR interactions, and by the activation state of downstream transcriptional switches, which regulate cytokine and chemokine cascades, the recruitment and activation of inflammatory cells and the effector functions required to clear bacteria from infected tissue sites. Early studies showed that UPEC strains activate epithelial IL-6, IL-1, TNF and IL-8 production, providing a link between microbial recognition by epithelial cells and neutrophil-dependent inflammation. Subsequent studies and proteomic screens have extended the repertoire of inflammatory mediators and responding host cells to include nerve cells, mast cells, lymphocytes and NK cells, among others. The mechanism of neutrophil recruitment involves specific chemokines, such as CXCL8, KC and MCP1, and the CXCR1 receptor is required for neutrophil activation, bacterial clearance and neutrophil exit from infected tissues into the urine, a prerequisite for avoiding tissue damage. Extended gene expression profiling of infected cells and tissues has been used to characterize key transcriptional regulators of the innate immune response in the kidneys, including IRF3 and IRF7, MYC and NF-κB, and gene deletion studies in mice have shown IRF3, IRF7 and CXCR1 to be disease regulators. Extended gene hyper-activation is rapid and pronounced in Irf3−/− mice, owing to Irf7 hyper-activation and a gene network comprising IL-6, TLR4, FOS and STAT3 [REF.].

### Virulence determinants in APN strains

APN strains are efficient pathogens defined by co-ordinately regulated virulence genes, which engage in multiple parallel mechanisms of tissue attack. Efficient bacterial adherence characterizes the disease isolates, providing a mechanism for

---

**Table 1 | Mouse single-gene knockout models**

| Mouse strain | Outcome of infection | Refs |
|--------------|----------------------|------|
| Tlr4−/−      | High bacterial counts, low PMN influx, prolonged infection, no symptoms of disease | 60   |
| Trif−/−      | High bacterial counts, low PMN influx | 60   |
| Tram−/−      | High bacterial counts, low PMN influx | 60   |
| Myd88−/−     | High bacterial counts, luminal PMN aggregates | 60   |

**Cystitis, recurrent UTI**

| Mouse strain | Outcome of infection | Refs |
|--------------|----------------------|------|
| Nlrp3−/−     | High bacterial counts, influx of leukocytes | 33   |
| Asc−/−       | High bacterial counts, influx of leukocytes | 33   |
| Tlr11−/−     | Prolonged infection and inflammation at later time points | 119  |
| Trx2−/−      | High bacterial counts, influx of leukocytes | 182  |
| Cd14−/−      | High bacterial counts in bladder | 189  |
| Ptx3−/−      | Increased susceptibility, high bacterial counts in bladder and kidneys | 179  |
| Il17a−/−     | Increased susceptibility, fewer PMNs | 205  |
| Tcrd−/−, Ifnb1−/−, Il4−/− | Increased susceptibility | 242  |

**Acute pyelonephritis**

| Mouse strain | Outcome of infection | Refs |
|--------------|----------------------|------|
| Irf3−/−      | Severe APN, acute mortality, sepsis, high bacterial counts, large renal abscesses | 12,34 |
| Ifnb1−/−     | Severe APN, acute mortality, sepsis, high bacterial counts, large renal abscesses and pathology | 32   |
| Cxcr2−/−     | Severe APN, acute mortality, sepsis, high bacterial counts, large renal abscesses and pathology | 31,104,169 |
| Il6−/−       | Severe APN, high bacterial counts | 156  |
| CAMP−/−      | High bacterial counts, pathology and severe symptoms | 174  |
| Thp−/−       | High bacterial counts | 188  |
| Nod2−/−      | Kidney abscesses | 241  |
| Thrombomodulin−/− | Elevated bacterial loads | 244  |
| P2x7−/−, P2x4−/− | Increased sensitivity to sepsis | 245  |

**Resistant phenotype**

| Mouse strain | Outcome of infection | Refs |
|--------------|----------------------|------|
| Irf7−/−      | Highly resistant to UTI | 34   |
| Il1b−/−      | Highly resistant to UTI | 15,60 |
| Atp16l1−/−   | Increased bladder clearance, protection | 246  |
| C5ar1−/−     | Protected against kidney infection | 247  |
| Nos2−/−, Il10−/− | No increased susceptibility | 242  |
| S100a9−/−    | Intact response, clearance | 248  |
| Tlr2−/−      | Intact response, clearance | 60   |
| Casp1−/−, Mmp7−/− | Intact response, clearance | 33   |

APN, acute pyelonephritis; PMN, polymorphonuclear neutrophil; UTI, urinary tract infection.
the pathogen to engage with the host. Extensive studies have subsequently defined a number of bacterial virulence factors\textsuperscript{104,105} and increased understanding of virulence and the niche-specific adaptation to the urinary tract environment\textsuperscript{106}. The presence of large chromosomal islands distinguishes pathogenic strains from non-pathogenic \textit{E. coli} \textit{K-12} strains\textsuperscript{107}. PAI- \textit{CFT073}-\textit{serU} and PAI- \textit{CFT073}-\textit{pheU}, harbouring \textit{P fimbriae} and \textit{TcpC} genes, are more strongly associated with APN and urosepsis than with ABU or cystitis\textsuperscript{108}. PAI deletions reduce virulence\textsuperscript{109}, despite fully functional virulence genes on other PAIs, suggesting a regulatory role\textsuperscript{110}.

**Adhesins and other virulence factors, expressed by uropathogenic \textit{E. coli}**. The interplay between fimbrial adhesins and host receptors provides molecular keys to innate immune activation and tissue access of additional virulence factors\textsuperscript{60,111,112}. \textit{P} fimbriae provide a direct disease-associated mechanism of tissue attack, by enhancing adherence, activating TLR4 signalling and activating the expression of the APN-associated transcription factor IRF7 (REFS\textsuperscript{34,79}) (FIG. 6). P-fimbriated \textit{E. coli} activate ceramide release by binding to receptor motifs present in the extracellular oligosaccharide domains of glycosphingolipid receptors, overriding the mucosal inertia to LPS\textsuperscript{113–115}. Downstream signalling involves the TLR4 adaptor proteins TIR domain-containing adapter molecule 2 or TICAM2 (TRAM) and TIR domain-containing adapter molecule 1 or TICAM1 (TRIF) (FIG. 6), the phosphorylation of mitogen-activated protein (MAP) kinases, phospholipase Cγ, p38, activating JUN N-terminal kinases (JNKs), CREB (cyclic AMP response element-binding) and IRF-dependent and AP-1-dependent transcription of cytokines and chemokines, as well as type I interferons including IFNβ\textsuperscript{32,116}. \textit{P} fimbriae are expressed by up to 100% of
APN and urosepsis strains but are rare in ABU strains, unlike type 1 fimbriae.

Other virulence-associated adhesins in APN strains include the Dr adhesin family of fimbrial and afimbrial components and S fimbriae that bind to the mucosa and type IV collagen on basement membranes, facilitating invasion. Type 1 fimbriae contribute to the pathogenesis of APN in the mouse UTI model but are not directly associated with virulence in epidemiological studies, suggesting a different role.

Endotoxins and exotoxins are important for bacterial tissue attack and act either directly as cytotoxic agents or indirectly by triggering inflammation and tissue damage. Uropathogenic strains produce haemolysin, which is toxic to kidney cells and causes urothelial damage and haematuria. The precise mechanism of action of the E. coli haemolysin and the pore formation is still debated, as most studies of haemolysin suggest a role in haemolysis. Uropathogenic strains produce haemolysin and the pore formation expressed by UPEC strains are essential in vivo, activating a Toll-like receptor 4 (TLR4) signalling cascade. Downstream MAP kinase signalling converges on p38, which controls the phosphorylation and activation of interferon regulatory factor 3 (IRF3), as well as NF-κB and activator protein 1 (AP-1); a heterodimer of FOS and JUN. IRF7 activation requires de novo synthesis followed by phosphorylation. IRF3 and IRF7 control disease severity by regulating different aspects of the antimicrobial defence and the inflammatory response of mice infected with UPEC strains. IRF3 is essential for the protective response and mice lacking IRF3 (Irf3−/− mice) develop severe acute infection with sepsis and mortality, followed by renal damage. Downstream mediators such as IFNβ are of crucial importance for the IRF3-dependent defence to occur and Ifnb1−/− mice develop a similar disease phenotype when infected with UPEC strains. By contrast, IRF7 drives disease and tissue pathology and mice lacking IRF7 (Irf7−/− mice) are protected from acute pyelonephritis. In addition, PapG is internalized and engages the IRF7 promoter complex together with IRF3, IFNβ and MYC. The PapG adhesin acts as a transcriptional IRF7 agonist, affecting the repertoire of genes expressed during acute pyelonephritis. Human promoter polymorphisms predicted to affect the susceptibility to acute pyelonephritis by reducing the expression of IRF3 have been detected in about 70% of patients with acute pyelonephritis. Attenuating IRF7 polymorphisms have been detected in asymptomatic bacteriuria. ABU, asymptomatic bacteriuria; APN, acute pyelonephritis; CREB, cyclic AMP response element-binding; Irf3−/− mice; Irf7−/− mice; Ifnb1−/− mice; APN, acute pyelonephritis; CREB, cyclic AMP response element-binding; P, phosphate group; SNP, single-nucleotide polymorphism; UTI, urinary tract infection. Adapted from REFP. © Springer Nature Limited, and from REFP, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
virulence-associated expression pattern and promotes persistence in the urinary tract\footnote{142}. Lipocalin 2 binds and sequesters enterobactin, a siderophore implicated in iron acquisition\footnote{143}. UPEC strains can also escape the host defence by glycosylation of enterobactin, and the product known as salmochelin is not recognized by its ligand lipocalin 2 [REFS\textsuperscript{135,136}].

Flagella, capsular polysaccharides and immune evasion proteins all contribute to the disease process by supporting the ascent of bacteria to the upper urinary tract\footnote{146} and conferring resistance to antibacterial effectors of inflammation. Flagella are essential for bacterial motility and to enable bacteria to ascend from the infected bladder into the renal pelvis. Flagella have been shown to engage TLR5 and activate innate immune signalling\footnote{137}. The uptake of UPEC strains by renal cells is supported by opsonization of bacteria with the complement component C3 and the presence of epithelial cell membrane C3 receptors\footnote{138}.

Studies of individual virulence factors clearly support their effects in cellular systems and animal models, but further studies are required to evaluate their specific contributions to disease alone or in combination.

**TIR domain proteins in UPEC strains suppress the innate immune response to virulent strains.** Given the central role of the TLRs in the host defence\footnote{127,129,138}, unsurprisingly, bacteria have evolved mechanisms to specifically interfere with TLR-mediated immune responses. TIR domain homologues have been detected in plants, mediating pathogen detection and defence responses\footnote{139}, and in bacteria, viruses and archaea, illustrating the importance of this protein family\footnote{140–144}. The ancestral prokaryotic TIR domains have been found to act as NADase enzymes, cleaving NAD\(^+\) into nicotinamide and ADP-ribose, therefore regulating oxidoreduction processes and cellular metabolism\footnote{145}. In bacteria, TIR-containing proteins (TcpS) suppress innate immunity in mice with UTI\footnote{146}. A TIR homologue is present in the genome of UPEC CFT073 and the bacteria secrete inhibitory TIR domain homologues that interfere with TLR signalling by competitive binding to MyD88 in vitro\footnote{140,144}. TcpC is most commonly expressed in virulent UPEC strains and has been shown to promote bacterial survival and kidney pathology in a mouse UTI model\footnote{147}. These observations suggest that pathogens are capable of directly modifying the TLR-dependent host defence by using TIR domain homologues.

**UPEC strains produce inhibitors of the MYC oncogene.** The bacteria–host interaction model helps in the discovery of molecules with biologically relevant effects in diseases other than UTI. In addition to producing molecules that directly affect virulence, UPEC strains were shown to inhibit and degrade the MYC oncogene protein\footnote{148}. Cancer cells are fast growing, outcompete non-malignant cells and spread to distant sites, where they cause metastasis\footnote{149}. Understanding what makes cancer cells so efficient and threatening is crucially important, and stopping them has always been the goal of cancer research. Early studies identified oncoproteins; genes that normally control cell growth but when mutated can be responsible for oncogenic transformation and explain the competitive advantage of cancer cells\footnote{150}.

The pleiotropic transcription factor MYC has been named ‘the quintessential oncogene’ and is hyperactive in the majority of human cancers\footnote{151}. Targeting MYC is, therefore, highly desirable. Myc inhibition clearly arrests cancer progression and restores tissue integrity in transgenic mouse models\footnote{149,152} and a vast number of technologies have been applied in attempts to target MYC and its different co-factors in cancer cells. Still, finding MYC inhibitors for therapeutic use has been problematic and MYC itself has long been viewed as undruggable\footnote{153}.

Surprisingly, UPEC strains deplete MYC protein from infected cells and tissues as a result of accelerated MYC protein degradation and attenuated MYC expression\footnote{146}. This bacterial strategy was translated to cancer therapy, demonstrating that Lon protease treatment is efficacious in slowing cancer progression and increasing survival\footnote{146}. The bacterial Lon protease is shown to rapidly degrade MYC without affecting MAX and other upstream regulators such as AKT, CDK9 or CPEB1, suggesting a high degree of specificity for MYC\footnote{146}.

The Lon protease is a conserved, ATP-dependent serine protease that maintains homeostasis in prokaryotes by processing short-lived regulatory proteins\footnote{152}. The Lon protease targets MYC in a variety of cancer cells\footnote{146}, including Burkitt lymphoma cells, in which MYC was first discovered\footnote{153}. Gene expression profiles in Lon-treated tissues showed a strong inhibitory effect on cancer-related genes, but no major effects on other gene categories, also supporting the potential of this therapeutic approach\footnote{146}.

These results suggest that bacteria have evolved strategies to control MYC tissue levels in the host. As MYC drives renal development\footnote{154}, and APN is a substantial cause of renal growth retardation\footnote{155}, MYC overexpression might have evolved to protect local host environments against detrimental effects of pathogenic bacteria. Speculatively, by inhibiting mucosal MYC expression bacteria might inadvertently provide a defence against oncogenic transformation.

**Genetic control of APN susceptibility**

Infections constitute a major evolutionary driving force, selecting resistance traits in infected hosts and bacterial genome alterations that enhance persistence. UTIs are an excellent example, as the most severe infections cause considerable mortality and impaired renal health, and, in women specifically, reduced fertility and premature delivery, starting from childhood. Host susceptibility is now being associated with inherited genetic traits and bacteria shown to evolve by loss of virulence, facilitating symbiosis and long-term persistence.

Genes that control immune activation and essential effector functions in APN have been identified using cellular infection models, animal models and clinical studies\footnote{131,132,134,136–138}. Specific genes have been shown to control APN severity by affecting initial disease activation, transcriptional regulators of inflammatory cascades, cellular antibacterial effector functions and mechanisms of tissue repair\footnote{144} (FIG. 6; TABLE 2). Further
Table 2 | Gene-association studies in patients

| Genetic variant | Biological effect | Disease association | Refs |
|-----------------|-------------------|---------------------|------|
| TLR4 promoter SNPs | Reduced promoter activity, low TLR4 expression | ABU | 16,249 |
| TLR2 coding region SNP | NR | ABU and recurrent UTI | 250 |
| TLR1, TLR2, TLR4, CXCR1, CXCR2 SNPs | NR | ABU | 81 |
| IRF7 promoter SNP | Low IRF7 expression | ABU | 14 |
| CXCR1 intronic SNP | Reduced promoter activity, low CXCR1 expression | APN | 157,171 |
| CXCR1 3′ UTR SNP | Increased 3′-mRNA processing | APN | 157,172, 251 |
| IRF3 promoter SNPs | Low promoter activity | APN | 32 |
| CXCL8 promoter and 3′ UTR SNP | NR | APN | 158, 251–254 |
| CCL5 promoter SNP | NR | APN | 181 |
| IL10 promoter SNP | NR | Recurrent APN | 180 |
| NLRP3 intronic SNP | NR | Negative association with APN | 255 |
| LTA coding region, TNF promoter SNP | NR | Recurrent UTI | 256 |
| HSPA1B coding region SNP | NR | Recurrent UTI | 257 |
| TLR1, TLR4, TLR5 coding region SNP | NR | Recurrent UTI | 83 |
| DEFA1A3 copy number | Low copy number | Recurrent UTI | 258 |
| TGFβ1, VEGFA promoter SNP | NR | UTI | 259 |
| TLR4 coding region SNP | Low monocyte and/or neutrophil expression | UTI | 257, 260–261 |
| PTX3 intronic SNP | NR | UTI | 278 |
| VDR (vitamin D receptor) coding region and intronic SNP | NR | UTI susceptibility | 264 |
| DNA copy number variations | Enrichment in innate immunity and development genes | UTI susceptibility in patients with VUR | 257 |

ABU, asymptomatic bacteriuria; APN, acute pyelonephritis; NR, not reported; SNP, single-nucleotide polymorphism; TLR4, Toll-like receptor 4; UTI, urinary tract infection; UTR, untranslated region; VUR, vesicoureteral reflux.

Evidence that APN susceptibility is genetically controlled was obtained in a three-generation family study. Inheritance of APN susceptibility was documented as an increase in APN frequency in both male and female children from families diagnosed with APN compared with children from families without UTI. Cystitis morbidity was not inherited in these families, supporting the notion that different mechanisms control the susceptibility to APN and cystitis (Table 2).

Genetic control of transcriptional regulation. Gene knockout studies have been used to identify key activation steps of the innate immune response to infection. Inactivating TLR4-tir domain mutations or Tlr4 deletions inhibit innate immune activation in mice, resulting in a phenotype that resembles ABU. Signalling cascades downstream of TLR4 converge on specific transcription factors (including IRF3, IRF7, AP1, NF-kB) and their role as regulators of UTI severity has been evaluated using gene knockout technology and in clinical studies [18, 24]. The closely related transcription factors IRF3 and IRF7 form heterodimers that regulate the activation of type I interferons and interferon-dependent genes, especially during viral infections [19, 20]. However, in APN, these transcription factors have opposite functions. After UPEC infection, mice lacking the transcription factor Irf3 develop severe disease, accompanied by urosepsis and massive renal abscess formation [21, 22]. IFNβ is activated downstream of IRF3, and Ifnb1−/− mice showed a similar phenotype to Irf3−/− mice, in the same infection model.

By contrast, Irf7−/− mice were protected from acute renal inflammation and showed no evidence of kidney pathology [23], suggesting that IRF7 might drive kidney pathology [24, 25]. IRF7-dependent gene networks were strongly upregulated in Irf3−/− mice infected with the UPEC strain CFT073, including an Irf7-dependent gene network comprising Stat3, Tlr4 and Il6 and downstream genes involved in the acute phase response. Binding of IRF7 to promoter DNA fragments (OAS1, CCL5 and INFB1) was demonstrated, confirming the role of IRF7 as a transcriptional regulator. IRF7 was further identified as an important transcriptional mediator during group B streptococcus-induced UTI in mice, suggesting a role during infections with Gram-positive pathogens as well [26].

The human relevance of these findings was supported by the detection of an IRF3 promoter sequence variants in two APN-prone patient populations. The homozygous A/A–C/C genotype (nucleotide positions −925 and −776) was prevalent in patients prone to APN (79%), whereas the co-segregating heterozygous SNPs were more common in patients with ABU (69%). The APN haplotype was shown to decrease IRF3 expression in reporter assays, suggesting that IRF3 needs to be fully functional to avoid APN [27].

The protective phenotype in Irf7−/− mice and overactivation of Irf7 in disease-prone Irf3−/− mice identified IRF7 as a potential therapeutic target. Support for this hypothesis was obtained using an siRNA-based strategy of Irf7 inhibition [28]. SiRNA treatment of Irf7−/− mice infected with the UPEC strain CFT073 was shown to inhibit the excessive and destructive innate immune response and to improve bacterial clearance, resulting in resolution of infection by day 7. siRNA therapy compared favourably with antibiotic treatment (ceftazidime treatment, 100 mg/kg) and Irf7 siRNA treatment was able to significantly reduce the disease score, including the number of kidney abscesses, by 95% compared with untreated mice (P < 0.01).

Prospective studies of genetic predisposition in childhood. The extent of genetic predisposition to APN and renal scarring has been investigated in two population-based studies. Children with a first febrile UTI episode were investigated and renal involvement was defined using dimercaptosuccinic acid (DMSA) scans. Inclusion criteria were matched, and the age range of the patients was 1 month to 2 years in population I and 3–5 months in population II. Molecular
susceptibility determinants were identified using exome genotyping, and effects of infection and host genotype on gene expression were analysed in detail. According to preliminary findings, APN is a disease with a strong genetic component, affecting acute renal involvement and disease severity (C.S., unpublished work).

**Genetic determinants of neutrophil infiltration and pathology.** APN is characterized by excessive neutrophil recruitment, neutrophil accumulation and inefficient bacterial clearance from infected kidneys. Early studies detected a rapid TLR4-dependent urine neutrophil response in the mouse model of UTI and the IL-8 family of chemokines (CXCL8) was shown to be activated during APN in mice and patients. The importance of neutrophils in the antimicrobial defence of the kidneys has been documented using genetic studies, anti-inflammatory agents, bone-marrow transplants and functional assays.

Gene knockout studies revealed that control of the neutrophil response is essential to clear the infection and maintain tissue integrity. The defective neutrophil recruitment, in, for example, Tlr4−/− mice, protected the tissues from acute pathology but bacterial clearance was not achieved, creating an ABU-like state. Mice lacking a key receptor for the IL-8 chemokine family (Cxcr2−/− mice), developed severe APN with urosepsis and acute mortality. Surviving mice developed renal scarring, with pathology similar to human pyelonephritis. This outcome was explained by a neutrophil migration deficiency, resulting in neutrophil accumulation in infected kidneys owing to an inability to cross the pelvic epithelium into the urine and to scavenge and kill the bacteria. The trapped neutrophils with their content of bacteria and debris became highly toxic for the renal parenchyma, resulting in renal scar formation. These results illustrate the importance of chemokines and their receptors for the control of neutrophil recruitment and bacterial clearance from infected kidneys.

In patients with APN, susceptibility is accompanied by low CXCR1 expression and CXCR1 mRNA levels. Patients prone to APN carry heterozygous CXCR1 polymorphisms attenuating receptor mRNA levels and protein expression. The presence of CXCR1 variants has been confirmed in several APN-prone patient groups. Furthermore, SNPs affecting IL-8 expression (CXCL8) were detected in patients with renal involvement confirmed by positive DMSA scans, supporting the relevance in human UTI.

**Other effector functions of the innate immune response.** Antibacterial peptides from infected tissues and inflammatory cells are potent effectors of the renal defence against infection (such as β-defensins, ribonucleases and cathelicidin). RNase 7 and cathelicidins act by disrupting the phospholipid membranes of various microorganisms and are constitutively synthesized by the kidneys. Lipocalin 2 (LCN2 or NGAL) is an antibacterial protein secreted both in the urine and systemically after Gram-negative infection, kidney injury or urosepsis. LCN2 binds the bacterial siderophore enterobactin, preventing iron transfer and sequestration by the bacteria. The humoral pattern recognition molecule pentraxin 3 (PTX3) serves as an opsonin and promotes bacterial uptake by neutrophils. PTX3 is polymorphic in UTI-prone children and adults (Table 2). Polymorphisms affecting IL10 were identified in APN-prone patients as well as SNPs in the CCL5 gene encoding the eosinophil product and T cell chemoattractant RANTES. In mice, a loss-of-function mutation affecting Tlr11 increased bacterial burden and leukocyte infiltration compared with wild-type mice in a UTI model. TLR11 is strongly expressed in mice but the human TLR11 gene is defective and human relevance remains unclear.

Taken together, these observations suggest that a combined effect of bacterial ‘super virulence factors’ and host susceptibility converge to cause severe disease in patients with APN. Starting from bacterial adherence and TLR4-mediated signalling, a blantant host response takes place with increased severity depending on the host genetics.

**Acute cystitis**

Acute cystitis is characterized by a pronounced mucosal inflammatory response in the lower urinary tract. Patients experience frequency, dysuria and suprapubic pain, often accompanied by haematuria and pyuria. A systemic host response is not typically seen, and unlike APN, acute cystitis is not accompanied by fever and general malaise. However, recurrent episodes of acute cystitis are common and can become debilitating, especially in subsets of susceptible patients who develop interstitial cystitis and/or bladder pain syndrome as a result of prolonged mucosal inflammation and nerve excitation.

**Genetic control of severity**

The molecular determinants of disease severity in acute cystitis have been unclear; however, mechanisms of innate immune hyper-activation have now been identified using a combination of cellular infection technology, animal models and clinical studies. The results show that acute cystitis is an IL-1β-driven, hyperinflammatory disorder of the infected urinary bladder driven by atypical IL-1β processing through matrix metalloproteinase 7 (MMP7) (Fig. 7). The results also suggest a genetic susceptibility mechanism of severe cystitis through mutations affecting IL1 as well as ASC and NLRP3 expression.

Pro-IL-1β is normally processed by the NLRP3 inflammasome, leading to transient, self-limiting inflammation in the bladders of C57BL/6 wild-type mice with an intact inflammasome. Il1b−/− mice were protected and the effect was similar to that previously observed in Tlr4−/− mice, suggesting that IL-1β is essential to drive the inflammatory response to bladder infection. Paradoxically, Asc−/− and Nlpr3−/− mice carrying inflammasome gene deletions developed severe, progressive bladder disease with large, hyperaemic bladders, loss of bladder tissue integrity and elevated bacteria counts, accompanied by IL-1β hyper-activation. An alternative mechanism of pro-IL-1β processing was detected in these severely ill mice, using gene expression analysis.
of bladder tissue. The metalloproteinase \textit{Mmp7} was transcriptionally hyperactivated (about 200-fold) and was shown to cleave pro-IL-1β, generating excessive amounts of active IL-1β in mice and human bladder cells\cite{15}. ASC and/or NLRP3 were further identified as transcriptional repressors of the \textit{Mmp7} promoter, providing an explanation for the observed MMP7 over-activation in \textit{Asc}−/− and \textit{Nlrp3}−/− mice\cite{15}.

Further experiments have indicated that \textit{Tlr5}, \textit{Thp} and \textit{Cox2} also modify innate immunity to UTI and that

Fig. 7 | Host determinants of disease severity in acute cystitis: mechanism of IL-1β and SP hyperactivation. Acute cystitis is a disease caused by excessive inflammation in the urinary bladder, accompanied by pain, frequency of micturition and urgency. The molecular basis of disease is illustrated here, focusing on the host determinants of disease and especially the IL-1β response. Left panel: bacteria engage urothelial cell receptors and trigger the expression of pro-IL-1β by activating Toll-like receptor 4(TLR4) signalling through the MyD88 adaptor pathway and the transcription factor NF-κB. IL-1β is essential for disease pathogenesis, as shown by the protection from acute cystitis in \textit{Il1b}−/− and \textit{Tlr4}−/− mice, which lack the pro-IL-1β response to infection with uropathogenic \textit{Escherichia coli} (UPEC) strains. Middle panel: bacteria activate the NLRP3 inflammasome via a second signal involving mechanisms such as ion fluxes. Activated caspase 1 (Casp-1) then cleaves pro-IL-1β to its mature and active form. The release of IL-1β triggers inflammation in the bladder and creates transient, mild disease in C57BL/6 wild-type mice. Right panel: in inflammasome-deficient mice an alternative IL-1β-processing mechanism takes over. Mice lacking the NLRP3 inflammasome owing to single gene deletions (\textit{Asc}−/− or \textit{Nlrp3}−/− mice) develop an IL-1β hyper-activation syndrome explained by excessive processing by matrix metalloproteinase 7 (MMP7)\cite{33}. In addition, ASC and NLRP3 regulate the expression of the pain receptor neurokinin 1 receptor (NK1R; encoded by TACR1), by acting as transcriptional repressors of both \textit{Mmp7} and \textit{Tacr1}. ASC and NLRP3, therefore, act as molecular gatekeepers, defining the level of transcription of the pro-inflammatory response driven by pro-IL-1β, and the pain response, driven by NK1R and substance P (SP). In Asc−/− or Nlrp3−/− deficient mice, in which this gatekeeping function is lost, UPEC-infected mice develop severe acute cystitis, mediated by excessive MMP7 cleavage of pro-IL-1β and by overproduction of NK1R\cite{33}. ASC, apoptosis-associated speck-like protein containing a CARD; IkB, inhibitor of kB; MyD88, myeloid differentiation primary response protein 88; NF-kB, nuclear factor-kB; P, phosphate group; TIRAP, Toll/interleukin 1 receptor-domain-containing adaptor protein. Adapted from \textit{Ref.} 15, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).
mice carrying homozygous deletions have increased susceptibility to acute cystitis\(^\text{139,140,141}\) (Table 1). The bladders of UPEC-infected \(\text{Tlr}5^{-/-}\) mice showed prominent submucosal oedema with leukocyte infiltration, as well as focal microabscesses and accumulation of leukocyte-rich exudates on the bladder surface\(^\text{142}\). In infected \(\text{Tlr}5^{-/-}\) mice, bacteria were predominantly observed on the surface of the urothelium, with no evidence of intracellular bacterial communities. TLR5 polymorphisms have also been observed in patients prone to recurrent UTI\(^\text{143}\) but genetic variation affecting \(\text{Thp}\) and \(\text{Cox2}\) has not been reported.

**Molecular basis of pain**
Mechanisms of infection-associated pain have been studied in several infection models, including \(\text{S. aureus}\)-mediated pain and \(\text{Clostridium difficile}\)-induced colitis\(^\text{146,191}\). Pain is a hallmark of acute cystitis; however, the mechanism by which infection triggers pain sensing in the urinary tract has been unclear. Acute cystitis strains directly activate nerve cells in vitro and in the urinary bladder\(^\text{148}\) (Fig. 8). The pain-sensing machinery involves the neurokinin 1 receptor (NK1R) and substance P (SP), which are activated in isolated nerve cells and in the urinary bladder mucosa. This response was potentiated by IL-1β in vivo in infected mice and was inhibited by IL-1R antagonists, demonstrating an interdependence between the epithelial and nerve cell response circuits\(^\text{149}\). These results suggest that NK1R and SP influence the severity of acute cystitis through a neuroepithelial activation loop that controls pain and mucosal inflammation.

NK1R and SP have been identified as novel targets for immunomodulatory therapy as well as biomarkers of acute cystitis. IL-1 receptor antagonists and NK1R inhibitors have been used successfully to inhibit infection-induced pain in mice with acute cystitis\(^\text{150}\). Pain behaviour, defined by locomotion, hunching and rearing behaviour, was markedly attenuated, in parallel with inflammation and pathology.

Clinical relevance was supported by off-label treatment of patients with bladder pain using an IL-1 receptor antagonist. A rapid reduction in pain and increase in the quality of life were recorded, suggesting considerable improvement after treatment.

**Innate immune mediators**
Early studies demonstrated that bladder epithelial cells produce cytokines in response to infection; a novel concept at the time\(^\text{152,165,192,193}\). Since then, numerous cytokines and chemokines have been detected in the urinary tract that mediate different aspects of the disease response\(^\text{150,194-198}\). The pro-inflammatory cytokine TNF, is rapidly and transiently expressed during the first days of infection\(^\text{155,195}\) and supports neutrophil recruitment and bacterial clearance in a mouse model of UTI\(^\text{196}\). The granulocyte colony-stimulating factor (G-CSF; also known as CSF3) is secreted during infection, and depletion using neutralizing antibodies decreased neutrophil recruitment into the bladder and increased bacterial clearance.
in infected mice. G-CSF induces the maturation of progenitor cells into neutrophils and promotes their systemic circulation. The chemokine CXCL12 is expressed in mice within hours of E. coli infection and promotes NK and T cell infiltration into the bladder. IL-17 influences disease severity and is differentially expressed between female and male mice following bladder infection. IL-17-depleted mice have reduced early urine neutrophils and increased bacterial burdens and IL-17 neutralization at the onset of infection leads to chronic UTI in female mice. Mechanistic studies further suggest that IL-17 might be crucial in restoring mucosal integrity after infection, also affecting chronicity.

Type 1 fimbriae

Why acute cystitis strains mainly infect the bladder and elicit a host response with molecular characteristics different from those seen in the kidneys remains unclear. Epidemiological studies have detected a high frequency of type 1 fimbriae among acute cystitis strains, but type 1 fimbrial expression does not show a clear disease association. Gene expression studies in infected mice suggest that type 1 fimbriae are expressed in the urinary tract, but the fimbriae were undetectable in acute isolates from women with UTI. Haemolysin and the prsG type of P fimbriae have been proposed to occur more often in acute cystitis strains than in other E. coli, but this association varies between study populations.

Type 1 fimbriae act as virulence factors in the mouse urinary tract and tissue interaction mechanisms have been extensively investigated. Type 1 fimbriae improve bacterial attachment to the bladder mucosa, where several mannosylated host cell glycoconjugates act as receptors for the FimH adhesin binds to the Tamm–Horsfall protein. THP, known as uromodulin, uroplakins (UPs), and CD48 on mucosal mast cells, as well as integrins β1 and α3. Type 1 fimbriae have been proposed to facilitate the invasion of mucosal cells and bacterial persistence and cystitis in mice. In humans, early findings of intracellular bacterial communities have not been confirmed.

Binding of type 1 fimbriae to UP1a stimulates the exfoliation of bladder epithelial cells, thereby shedding adherent bacteria and increasing access to underlying tissues. In response to FimH–FimC binding, UP3a phosphorylation activates casein kinase II and triggers calcium influxes and cyclic AMP regulates the incorporation of E. coli into fusiform vesicles and exocytosis of E. coli from bladder epithelial cells. Intraperitoneal forskolin treatment, which elevates intracellular levels of cyclic AMP, was reported to eliminate >99% of intracellular E. coli by exocytosis without affecting bacterial viability.

The relevance of these mechanisms to disease severity in acute cystitis remains unclear. Clear disease phenotypes have not been observed and consequences of these molecular effects for disease have not been clearly defined.

Mast cells in acute cystitis

Mast cell activation is important in the bladder mucosa and known effects of histamine and other mast-cell mediators correlate with the neuroinflammatory response and symptoms of acute cystitis. Pre-stored TNF-containing granules within mast cells have been shown to burst and participate in the recruitment and activation of neutrophils, and TNF activation and neutrophil recruitment was reduced in mast cell-deficient mice. Mast cells are activated by epithelial release of IL-1β, ATP, IL-33 and β-defensins, and the histamine response magnitude correlated positively with the number of adherent type 1 fimbriated bacteria. Type 1 fimbriea interactions with mast cell glycosyl-phosphatidylinositol receptors (CD48) were shown to affect the uptake of adherent bacteria as well as mast cell degranulation. The role of mast cells and their link to type 1 fimbriae are interesting and potentially important, but their role in host resistance and disease severity requires further study.

The shedding of superficial bladder epithelium during UTI is well known and UPEC infection was shown to trigger rapid desquamation in the 1980s. In later studies, cell shedding was attributed to granule-releasing mast cells as a mechanism to reduce the tissue-associated bacterial load. In a mouse model of induced recurrent cystitis, a lack of superficial terminal differentiation markers in umbrella cells was interpreted to indicate a lack of tissue repair. Susceptibility to recurrent UTI was positively correlated with cyclooxygenase 2 (COX2) expression, as would be expected from effects on innate immunity, but the effects of bacterial clearance varied, suggesting additional variables. Moreover, a strong T1,2 response was proposed to aid in repairing the superficial bladder epithelium following infection-triggered exfoliation of this barrier.

Taken together, these studies highlight the importance of host susceptibility for disease in the urinary bladder and identify IL-1 hyperactivation as a potent disease determinant with immediate human relevance. In addition, pro-inflammatory loops involving pain sensors provide an explanation for the pain response, especially in acute cystitis. Clinical studies provide support for these mechanisms, as IL-1 and the neuropeptide substance P both showed elevated levels in acute cystitis patients, compared with individuals with ABU.

Thus, these findings indicate that the use of immune response biomarkers should be explored to distinguish different forms of UTI and evaluate the level of immune activation in the patient.

Parallels with COVID-19 infection

The protective role of innate immunity and detrimental effects of excessive immune activation have become very obvious during the COVID-19 pandemic. The strategies of innate immune activation are conserved and the innate immune response to UTI shares several characteristics with the response seen in patients with COVID-19. For example, viral and bacterial ligands guide TLR4 activation. TLR4 has shown strong protein–protein interaction with the spike glycoprotein of SARS-CoV-2, leading to excessive TLR4 activation. Furthermore, SARS-CoV-2 has an affinity for linoleic acid, suggesting a potential parallel to P fimbriae, which bind to glycosphingolipid receptors and trigger the release of ceramide, consisting of sphingosine and...
fatty acids, which acts as a signalling intermediate in TLR4 activation14. Severely ill patients with COVID-19 have excessive production of pro-inflammatory cytokines and chemokines including IL-6 (REF.238), which is associated with disease severity and outcome in APN and urosepsis as well29. Finally, IL-1β levels are dramatically increased in patients with COVID-19 and MMP levels are elevated30, possibly indicating that the non-canonical processing mechanism of pro-IL-1β by MMP7, which is seen in acute cystitis, might contribute to this excessive response.

Conclusions

UTIs are a common cause of morbidity and mortality and impair the quality of life for large numbers of individuals. Every other woman is affected by acute cystitis at least once and recurrences and chronicity are extremely common. APN in childhood is a major cause of renal scar formation and renal growth retardation, increasing the risk of hypertension and chronic renal disease requirement for dialysis or transplantation in adulthood and also premature birth in women. Antibiotics have provided an essential therapeutic option, but owing to the rapid increase in antibiotic resistance, detailed molecular questions need answers in order to design effective novel interventions with sufficient precision. Specific molecular insights can, for the first time, provide appropriate tools to evaluate disease severity, susceptibility and future patient risk.

In this Review, we show how an overactive innate immune response can become a susceptibility factor in UTI, with debilitating consequences for the patients. The data also distinguish APN from acute cystitis, at the molecular level12–24. APN susceptibility is enhanced by a transcription factor imbalance and by immunodeficiencies affecting neutrophil-dependent bacterial clearance41. By contrast, acute cystitis is caused by IL-1β hyper-activation owing to mutations that inactivate the inflammasome constituents ASC and NLRP3. A compensatory route of pro-IL-1 processing by the MMP7 protease, is shown to result in excessive cleavage of pro-IL-1β, causing severe disease41. Thus, even when mice are infected with the same E. coli strain, the host decides the outcome.

The findings emphasize how weaknesses of the host create innate immune imbalances and immune hyperactivation disorders leading to disease. The results also provide the rationale for immunomodulation as a new therapeutic tool to deliberately modify host susceptibility, control the host response and avoid severe disease.

Published online 15 June 2021
Sunden, F., Hakansson, L., Ljunggren, E. & Wullt, B. Escherichia coli protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J. Urol. 184, 179–185 (2010).

Hull, R. et al. Urinary tract infection prophylaxis using Escherichia coli 85972 in spinal cord injured patients. J. Infect. 61, 172–176 (2010).

Dobrindt, U., Schwan, W. R., Hultgren, S. J. & Schaeffer, A. J. Evaluation of Escherichia coli on evolution of uropathogenic Escherichia coli. Clin. Infect. Dis. 191, 509–5107 (2009).

Selth, L. A., Sigurdsson, S. & Sveistrup, J. Q. Transcript elongation by RNA polymerase II. Annu. Rev. Biochem. 79, 271–293 (2010).

Linder, H., Engberg, I., Hoschutzky, H., Mattsby-Baltzer, I. & Svanborg, C. Adhesion- and new treatment strategies. Nat. Rev. Microbiol. 18, 211–226 (2020).

Lehrer, R. & Svanborg-Edén, C. LytM domain proteins of uropathogenic Escherichia coli on human erythrocytes and urethral epithelial cells. Infect. Immun. 34, 920–929 (1981).

Caugant, D. A. et al. Genetic diversity in relation to serotype in Escherichia coli. Infect. Immun. 49, 407–413 (1985).

van der Poel, H. et al. Uropathogenic Escherichia coli tlr4: central component of the sole mammalian LPS sensor. Science 326, 1278–1284 (2005).

Lehrer, R. & Svanborg-Edén, C. Glycolipid receptors for uropathogenic Escherichia coli on human erythrocytes and urethral epithelial cells. Infect. Immun. 67, 235–236 (1999).

Veijorég, R., M. Hancot, K., R., Konrad, M. S. & Klemm, P. Comparative genomic of Escherichia coli strains causing urinary tract infections. Appl. Environ. Microbiol. 77, 3263–3267 (2011).

Berg, G., Wullt, B. & Svanborg-Edén, C. Escherichia coli fimbiae, bacterial persistence and host response induction in the human urinary tract. Int. J. Med. Microbiol. 292, 187–195 (2002).

Hull, R. et al. Virulence properties of Escherichia coli 83972, a prototype strain associated with asymptomatic bacteriuria. Infect. Immun. 67, 429–426 (1999).

Mabbutt, A. N. et al. Virulence properties of asymptomatic bacteriuria Escherichia coli. Int. J. Med. Microbiol. 286, 225–232 (2006).

Takahashi, A. et al. Escherichia coli isolates associated with uncomplicated and complicated cystitis and asymptomatic bacteriuria possess similar phylogenies, virulence genes, and O-serogroup profiles. J. Clin. Microbiol. 44, 4589–4592 (2006).

Roos, V., Schember, M. A., Ulett, C. G. & Klemm, P. Asymptomatic bacteriuria Escherichia coli strain 83972 carries mutations in the foci locus and is unable to express FIC fimbiae. Microbiology 152, 1986–1998 (2006).

Wullt, B. et al. Fimbiae enhance the early establishment of Escherichia coli in the human urinary tract and protect against recurrent lower urinary tract infections. PLoS Pathog. 7, e1002175 (2011).

Sims, R. J. et al. Belotserkovskaya, R. & Reinberg, D. Elongation by RNA polymerase II. Proc. Natl Acad. Sci. USA 92, 384–388 (1995).

Gluba, A. et al. The role of Tlr4 receptors in renal diseases. Nat. Rev. Nephrol. 6, 224–235 (2010).

Gamaresyl, V. & Elsner, R. Early changes in CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit. Care 10, 1866–1902 (2006).

Smith, Y. C., Rasmussen, S. B., Grande, K. K., Conran, R. M. & Brien, A. D. Hemolytic of
unpathogenic Escherichia coli evokes extensive shedding of the uropathogen and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice. Infect. Immun. 76, 2978–2986 (2008).

125. Hildebrand, A., Pohl, M. & Bhakdi, S. Staphylococcus aureus alpha-toxin. Dual mechanism of binding to target cell. J. Biol. Chem. 266, 17195–17200 (1991).

126. Ludwig, A., Benz, R. & Goebel, W. Oligomerization of Escherichia coli haemolysin (HlyA) is involved in pore formation. Mol. Gen. Genet. 241, 89–96 (1993).

127. Wilke, G. A. & Bubeck Wardenburg, J. Role of a disintegrin and metalloproteinase 10 in Staphylococcus aureus alpha-toxin-induced intracellularly induced cell death. Proc. Natl Acad. Sci. USA 107, 15347–15348 (2010).

128. Mills, M., Mbeeld, K. C. & O'Brien, A. D. Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism. Infect. Immun. 68, 5869–5880 (2000).

129. Garcia, E. C., Brumbaugh, A. R. & Mobley, H. L. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect. Immun. 79, 1225–1235 (2011).

130. Henderson, L. C., Kadis, S. & Chapman, W. L. Jr. Influence of iron on Corynebacterium renale-induced pyelonephritis in mice. J. Urol. 179, 213–218 (2008).

131. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

132. Smith, K. D. Iron metabolism at the host pathogen interface. Front. Immunol. 10, 540 (2019).

133. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

134. Smith, K. D. Iron metabolism at the host pathogen interface. Front. Immunol. 10, 540 (2019).

135. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

136. Smith, K. D. Iron metabolism at the host pathogen interface. Front. Immunol. 10, 540 (2019).

137. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

138. Smith, K. D. Iron metabolism at the host pathogen interface. Front. Immunol. 10, 540 (2019).

139. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

140. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

141. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

142. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

143. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

144. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

145. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

146. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

147. Jacobson, S. H., Tullus, K., Wretlind, B. & Brauner, A. Redundancy and specificity of iron acquisition systems during urinary tract infection. Kidney Int. 82, 1415–1426 (2013).

148. Croce, C. M. Oncogenes and cancer. N. Engl. J. Med. 358, 502–511 (2008).

149. Peterson, L. L. & Evan, G. C. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764–776 (2002).

150. Souchek, J., et al. Modelling Myc as a cancer therapy. Nature 455, 679–683 (2008).

151. Chen, H., Liu, H. D. & Qin, G. L. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 5, 8 (2018).

152. Lee, I. & Suzuki, C. K. Functional mechanics of the ATP-dependent Lon protease-lesons from endogenous and exogenous substrate structures. Biochim. Biophys. Acta 1784, 727–735 (2008).

153. Ramsay, G., Evan, G. I. & Bishop, J. M. The protein encoded by the human c-myc protooncogene. Proc. Natl Acad. Sci. USA 81, 7742–7746 (1984).
on normal mouse hemagglutinic cells. J. Cell Physiol. 116, 198–206 (1983).

201. Barreda, D. R., Hanington, P. C. & Belosevic, M. Regulation of myosin development and function by coiled-coil stimulating factors. Dev. Comp. Immunol. 28, 509–554 (2004).

202. Marshall, J. C. The effects of granulocyte colony-stimulating factor on the viminoid and model infections of vimentin and acute inflammation. Shock 24 (Suppl. 1), 120–129 (2005).

203. Hargis, B. T. Stromal cell-derived factor 1 mediates immune cell attraction upon urinary tract infection. Cell Rep. 20, 40–47 (2017).

204. Zychlinsky Scharff, A. et al. Sex differences in IL-17 contribute to urinary tract infection. JCI Insight 5, e129981 (2020).

205. Beck, K. E., Schaller, M. A., Smith, S. N. & Mobley, H. L. The innate immune response to uropathogenic Escherichia coli involves IL-7 in a murine model of urinary tract infection. J. Immunol. 184, 2065–2070 (2005).

206. Wu, J. et al. A highly polarized TH2 bladder response to infection promotes epithelial repair at the expense of preventing new infections. Nat. Immunol. 21, 671–682 (2020).

207. Hagan, E. C., Lloyd, A. L., Rasko, D. A., Faerber, G. J. & Mobley, H. L. Escherichia coli global gene expression during urinary tract infection. PLoS Pathog. 6, e1001871 (2010).

208. Lindstedt, R. et al. The receptor repertoire defines the host immune response to urinary tract infection. J. Infect. Dis. 205, 580–590 (2012).

209. Johansson, I.-M., Plos, K., Marklund, B.-I. & Svanborg, C. Song, J. et al. A novel TLR4-mediated signaling mechanism. J. Clin. Invest. 184, 1276–1286 (1989).

210. Abraham, S. L., Shi, J. & Malavà, A. Type I adipotrophic Escherichia coli-mast cells interactions in cytokines. J. Infect. Dis. 205, 580–590 (2012).

211. Aronson, M., Medalla, O., Amichay, D. & Nativ, O. Endotoxin-induced shedding of viable uroepithelial cells is an antimicrobial defense mechanism. Infect. Immun. 56, 1615–1617 (1988).

212. Mulvey, M. A., Schultzing, J. D. & Hultgren, S. J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69, 4572–4579 (2001).

213. Chua, H. W. et al. Loss of bladder epithelium induced by cytolytic mast cell granules. Immunity 45, 1258–1269 (2016).

214. O'Brien, V. P. et al. A mucosal imprint left prior to urinary tract infection promotes recurrent disease. Nat. Microbiol. 2, 16196 (2016).

215. Hannan, T. J. et al. Inhibition of cytokine-2 prevents chronic recurrent cystitis. Environ. Bio Med. 1, 46–57 (2014).

216. O'Brien, V. P., Dorsey, A. A., Hannan, T. J. & Hultgren, S. J. Establishment of a persistent Escherichia coli urinary tract infection occurs in a bacterial strain-specific manner. PLoS Pathog. 14, e1007457 (2018).

217. Xie, B. et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398–401 (2000).

218. Neelli, L. A., Blevins, D. & Bowie, A. G. The history of Toll-like receptors — redefining innate immunity. Nat. Rev. Immunol. 13, 453–465 (2013).

219. Patra, R., Chatterjee, S. Targeting human TLRS to combat COVID-19: a solution? J. Med. Virol. 93, 615–617 (2020).

220. Teitzer, C. et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science 370, 725–750 (2020).

221. Huang, Q. et al. Targeting inflammation and cytokine storm in COVID-19. Pharmacol. Res. 159, 105051–105051 (2020).

222. Otto, C., Bracconier, J., Andreassen, A. & Svanborg, C. Formation of humanTLRs by epithelial cells in patients with bacteremic and nonbacteremic febrile urinary tract infection. J. Infect. Dis. 179, 172–179 (1999).

223. Fraser, D., Patterson, E., Daley, M. & Cepinskas, G. Cell Rep. Immunology and endothelial injury profiling of COVID-19 pediatric multisystem inflammatory syndrome. (MIS-C). Front. Pediatr. 9, 597926 (2021).

224. Carey, A. J. et al. Uropathogenic Escherichia coli engages CD48-bearing V1aR to enable bladder-macrophage-dependent control of acute urinary tract infection. J. Infect. Dis. 213, 659–668 (2016).

225. Jones- Carson, J., Balish, E. & Uehling, D. T. Characterization of iNOS deficiency-mediated resistance to urinary tract infection. J. Infect. Dis. 185, 16196 (2007).

226. Song, J. et al. A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. Urology 76, 560–567 (2009).

227. Thumherit, P. et al. Bacterial- induced uroplakin signaling mediates bladder response to infection. PLoS Pathog. 5, e1000415 (2009).

228. Bischof, B. L. et al. Cyclo-AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat. Med. 13, 625–630 (2007).

229. Malaiya, R., Ikeda, T., Ross, E. & Abraham, S. Mast cell monolayer influx and bacterial clearance at sites of infection through TLR4-NFAT. Nature 381, 77–80 (1996).

230. Varela, H. et al. Frasca, D. L. & Wu, X. R. Substance P-induced accumulation of cutaneous vascular permeability and granulocyte infiltration in mice is TLR4-dependent. J. Clin. Invest. 84, 1276–1286 (1989).

231. Abraham, S., Shin, J. & Malavà, A. Type I adipotrophic Escherichia coli-mast cells interactions in cytokines. J. Infect. Dis. 205, 580–590 (2012).

232. Yim, H. E., Bae, I. S., Yoo, K. H., Hong, Y. S. & Lee, J. W. Genetic control of VEGF and TGF-β1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux. Pediatr. Res. 62, 185–187 (2007).

233. Ahj, L. et al. Assessment of Toll-like receptor-4 gene polymorphism on pyelonephritis and renal scar. Int. J. Immunogenet. 39, 503–507 (2012).

234. Bayram, M. T., Soyka, A., Ates, H., Kizildag, S. & Kavukcu, S. TLR-4 polymorphisms and leucocyte TLR-4 expression in febrile UTI and renal scarring. Pediatr. Nephrol. 28, 1827–1835 (2013).

235. Pand, D. B., Singh, S. & Agrawal, N. K. Testing an association between TLR4 and CXCR1 gene polymorphisms with susceptibility to urinary tract infection in type 2 diabetes in north Indian population. Gene 641, 196–202 (2018).

236. Karamanou, P. et al. The role of TLR4, Asp299Gly and TLR5 Thr99Ile polymorphisms in the pathogenesis of urinary tract infections: first evaluation in infants and children of Greek origin. J. Immunol. Res. 2019, 465892 (2019).

237. Aryan, S. et al. Vitamin D receptor gene polymorphism in children with urinary tract infection. Pediatr. Nephrol. 27, 417–421 (2012).

Acknowledgements The authors gratefully acknowledge the support of the Swedish Research Council, Swedish Cancer Society, J.C. Forsman Foundations, Medical Faculty (Lund University), Royal Physiographic Society. Network of Excellence: Infect-ERA and ALF grants from the Medical Faculty and Regional Laboratories (Lambmedic Skåne), the European Union’s Horizon 2020 research and innovation programme (grant no. 954360) for support to the laboratory infrastructure.

Author contributions I.A., D.B., M.L.Y.W. and S.B. researched data for the article and wrote the manuscript. I.A., D.B., M.L.Y.W., J.T. and S.B. contributed to discussions of the content and I.A., D.B., M.L.Y.W. and S.B. reviewed and edited the manuscript before submission.

Competing interests Patents have been filed for the use of the NipD protein and IRF7 siRNA as immune modulators and for the use of IL-1R antagonists in the treatment of cystitis. The rights to develop these patents are held by SelectImmune Pharma, where the scientists I.A., D.B., M.L.Y.W. and S.B. hold shares T and S.M.C. declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. © Springer Nature Limited 2021